Cargando…

The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes

Immune checkpoint inhibitors (ICIs) cause a variety of inflammatory eruptions. The understanding of ICI-induced inflammatory eruptions with detailed histopathological findings is not adequate, particularly in Asian populations. In this study, we retrospectively reviewed 51 patients who were histopat...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashimoto, Hiroki, Ito, Takamichi, Ichiki, Toshio, Yamada, Yuichi, Oda, Yoshinao, Furue, Masutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918541/
https://www.ncbi.nlm.nih.gov/pubmed/33673164
http://dx.doi.org/10.3390/jcm10040728
_version_ 1783657946400423936
author Hashimoto, Hiroki
Ito, Takamichi
Ichiki, Toshio
Yamada, Yuichi
Oda, Yoshinao
Furue, Masutaka
author_facet Hashimoto, Hiroki
Ito, Takamichi
Ichiki, Toshio
Yamada, Yuichi
Oda, Yoshinao
Furue, Masutaka
author_sort Hashimoto, Hiroki
collection PubMed
description Immune checkpoint inhibitors (ICIs) cause a variety of inflammatory eruptions. The understanding of ICI-induced inflammatory eruptions with detailed histopathological findings is not adequate, particularly in Asian populations. In this study, we retrospectively reviewed 51 patients who were histopathologically diagnosed with cutaneous immune-related adverse events (irAEs) following ICI therapy between 2014 and 2020 at the Department of Dermatology of Kyushu University Hospital. Of the 51 patients (30 men, 21 women), maculopapular rash (38/51, 74.5%), erythema multiforme (2/51, 3.9%), lichenoid reaction (3/51, 5.9%), psoriasiform reaction (3/51, 5.9%), bullous pemphigoid (3/51, 5.9%), scleroderma-like reaction (1/51, 2.0%), and Stevens–Johnson syndrome (1/51, 2.0%) were observed. The clinical and histopathological findings of these eruptions were equivalent to typical cases of common drug eruptions. The onset of maculopapular rash was relatively early (more than half of events occurred within 1 month), whereas lichenoid reactions and autoimmune diseases occurred relatively late (4–8 months). With appropriate treatment and/or interruption of ICIs, most rashes improved (50/51, 98.0%). The ICI-induced inflammatory eruptions shared similar clinical and histopathological features with classical inflammatory eruptions, but a variety of inflammatory eruptions may occur with different degrees of severity. Dermatologists play an important role in providing specialized care for cutaneous irAEs.
format Online
Article
Text
id pubmed-7918541
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79185412021-03-02 The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes Hashimoto, Hiroki Ito, Takamichi Ichiki, Toshio Yamada, Yuichi Oda, Yoshinao Furue, Masutaka J Clin Med Article Immune checkpoint inhibitors (ICIs) cause a variety of inflammatory eruptions. The understanding of ICI-induced inflammatory eruptions with detailed histopathological findings is not adequate, particularly in Asian populations. In this study, we retrospectively reviewed 51 patients who were histopathologically diagnosed with cutaneous immune-related adverse events (irAEs) following ICI therapy between 2014 and 2020 at the Department of Dermatology of Kyushu University Hospital. Of the 51 patients (30 men, 21 women), maculopapular rash (38/51, 74.5%), erythema multiforme (2/51, 3.9%), lichenoid reaction (3/51, 5.9%), psoriasiform reaction (3/51, 5.9%), bullous pemphigoid (3/51, 5.9%), scleroderma-like reaction (1/51, 2.0%), and Stevens–Johnson syndrome (1/51, 2.0%) were observed. The clinical and histopathological findings of these eruptions were equivalent to typical cases of common drug eruptions. The onset of maculopapular rash was relatively early (more than half of events occurred within 1 month), whereas lichenoid reactions and autoimmune diseases occurred relatively late (4–8 months). With appropriate treatment and/or interruption of ICIs, most rashes improved (50/51, 98.0%). The ICI-induced inflammatory eruptions shared similar clinical and histopathological features with classical inflammatory eruptions, but a variety of inflammatory eruptions may occur with different degrees of severity. Dermatologists play an important role in providing specialized care for cutaneous irAEs. MDPI 2021-02-12 /pmc/articles/PMC7918541/ /pubmed/33673164 http://dx.doi.org/10.3390/jcm10040728 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hashimoto, Hiroki
Ito, Takamichi
Ichiki, Toshio
Yamada, Yuichi
Oda, Yoshinao
Furue, Masutaka
The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes
title The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes
title_full The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes
title_fullStr The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes
title_full_unstemmed The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes
title_short The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes
title_sort clinical and histopathological features of cutaneous immune-related adverse events and their outcomes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918541/
https://www.ncbi.nlm.nih.gov/pubmed/33673164
http://dx.doi.org/10.3390/jcm10040728
work_keys_str_mv AT hashimotohiroki theclinicalandhistopathologicalfeaturesofcutaneousimmunerelatedadverseeventsandtheiroutcomes
AT itotakamichi theclinicalandhistopathologicalfeaturesofcutaneousimmunerelatedadverseeventsandtheiroutcomes
AT ichikitoshio theclinicalandhistopathologicalfeaturesofcutaneousimmunerelatedadverseeventsandtheiroutcomes
AT yamadayuichi theclinicalandhistopathologicalfeaturesofcutaneousimmunerelatedadverseeventsandtheiroutcomes
AT odayoshinao theclinicalandhistopathologicalfeaturesofcutaneousimmunerelatedadverseeventsandtheiroutcomes
AT furuemasutaka theclinicalandhistopathologicalfeaturesofcutaneousimmunerelatedadverseeventsandtheiroutcomes
AT hashimotohiroki clinicalandhistopathologicalfeaturesofcutaneousimmunerelatedadverseeventsandtheiroutcomes
AT itotakamichi clinicalandhistopathologicalfeaturesofcutaneousimmunerelatedadverseeventsandtheiroutcomes
AT ichikitoshio clinicalandhistopathologicalfeaturesofcutaneousimmunerelatedadverseeventsandtheiroutcomes
AT yamadayuichi clinicalandhistopathologicalfeaturesofcutaneousimmunerelatedadverseeventsandtheiroutcomes
AT odayoshinao clinicalandhistopathologicalfeaturesofcutaneousimmunerelatedadverseeventsandtheiroutcomes
AT furuemasutaka clinicalandhistopathologicalfeaturesofcutaneousimmunerelatedadverseeventsandtheiroutcomes